Avricore Health Inc. is pleased to announce it will be placing its real-time reporting HealthTab™ systems in Oak Medical Art’s community pharmacy locations, bringing advanced point of care testing to Canada’s North for the first time. “HealthTab™ offers affordable screening solutions to communities where it just wasn’t possible before,” said Avricore Health’s CEO, Hector Bremner. “We think that ...

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is pleased to announce it will be placing its real-time reporting HealthTab™ systems in Oak Medical Art's community pharmacy locations, bringing advanced point of care testing to Canada's North for the first time.

"HealthTab™ offers affordable screening solutions to communities where it just wasn't possible before," said Avricore Health's CEO, Hector Bremner. "We think that everyone deserves access to healthcare data we're so happy to officially reach Canada's north!"

Pharmacies agree to a two-year lease commitment, as well as the purchase of reagent panels and other consumables from the Company. De-identified, statistical data can also be monetized, presenting additional revenue streams for the Company.

"Oak Medical Arts prides itself on innovation and putting patients at the center of everything we do," said Bryan Gray, Director of Oak Medical Arts. "By offering point-of-care testing to better understand our patient needs, we can deliver better service and support better health outcomes."

About HealthTab™ + RASTR

HealthTab™ is a proven point-of-care screening system, designed to support pharmacists' evolving role. The system empowers patients to be proactive about their health by directly measuring and monitoring key safety tests and biomarkers of chronic disease. The HealthTab™ test is simple, fast, lab-accurate, and requires just a few drops of blood from a finger stick. Results can be printed in-store or accessed securely online.

Typically, HealthTab™ utilizes the Piccolo Xpress, an Abaxis Global Diagnostics chemistry analyzer, however, the system is designed to interface with other devices and third-party applications.

As part of this direction for HealthTab™, the Company developed a revolutionary model for utilizing the system's unique ability to offer real-time evaluations of treated populations and even real-world evaluation clinical trials.

The name for this approach is Rapid Access Safety Test Reporting, or RASTR Network, whereby the network of HealthTab™ systems feedback de-identified data through to electronic health records and data management systems via its API capabilities. This is the first platform of harmonized analyzers, with fully integrated data-flow, for blood chemistry results to be sent to consumers, their healthcare teams and sponsors, such as researchers, insurance providers and the life-science sector.

The significance of this approach to the market is the enhanced access to screening and early detection of disease, better data for physicians and pharmacists to support their patients, plus new opportunities to conduct research and ensure patient safety.

About Avricore Health Inc.
Avricore Health Inc. is committed to becoming a health innovator and applying technologies at the forefront of science to core health issues at the community pharmacy level. The Company's goal is to empower consumers, patients and pharmacists with innovative technology, products, services and information to monitor and optimize health. www.avricorehealth.com

Contact:

Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical Approved by TSXV and Closed

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical Approved by TSXV and Closed

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, it has received TSXV approval, and has closed its acquisition of a 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
Leveljump Healthcare Strengthens Board of Directors

Leveljump Healthcare Strengthens Board of Directors

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce new additions to its board of directors and its advisory board.

Gary Prihar - Director

Keep reading... Show less
ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, is pleased to announce the signing of a Memorandum of Understanding ("MOU") with Infinovo Medical Co. Ltd for a global supply agreement of their P3 Continuous Glucose Monitor (CGM) for use by ALRT in the animal health sector.

Under the terms of the MOU, ALR Technologies and Infinovo will collaborate to integrate Infinovo's P3 CGM with ALRT's proprietary GluCurve platform. The Company expects to begin testing the GluCurve Pet CGM in veterinary clinics in late December 2021 or early January 2022. The testing is scheduled to complete by the end of February 2022.

Keep reading... Show less

Medtronic Hugo robotic-assisted surgery system receives Health Canada licence, further enabling access to robotic-assisted surgery in Canada

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), the world's leading medical technology company, announced it has received a Health Canada licence for the Hugo™ robotic-assisted surgery (RAS) system for use in use in urologic and gynecologic laparoscopic surgical procedures, which make up about half of all robotic procedures performed today. 1

Keep reading... Show less

APMA Grants Seal of Approval for JUBLIA® Topical Solution, 10%

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA ® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

Keep reading... Show less

Johnson & Johnson COVID-19 Booster, Administered Six Months After Two-Dose Regimen of BNT162b2, Shows Substantial Increase in Antibody and T-cell Responses

- Johnson & Johnson (NYSE: JNJ) (the Company) today announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center (BIDMC), which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv .

"There is early evidence to suggest that a mix-and-match boosting approach may provide individuals with different immune responses against COVID-19 than a homologous boosting approach," said Dan Barouch , M.D., Ph.D., Director of the Center for Virology and Vaccine Research at BIDMC. "In this preliminary study, when a booster dose of Ad26.COV2.S was given to individuals six months after a primary regimen with the BNT162b2 vaccine, there was a comparable increase of antibody responses at week four following the boost and a greater increase of CD8+ T-cell responses with Ad26.COV2.S compared with BNT162b2."

Keep reading... Show less

Top News

Related News